Key result
Bevacizumab combined with chemotherapy linked to fatal concurrent cerebral infarction and pulmonary embolism.
Why the study?
Fatal concurrent arteriovenous thromboembolism following bevacizumab combined with chemotherapy had not been previously reported.
Case Report (n=1)
Bevacizumab combined with chemotherapy may increase the risk of fatal arteriovenous thromboembolism in patients with advanced lung cancer.
Answers are grounded in this paper and cite their sources.
Fatal thromboembolism on bevacizumab in advanced NSCLC warrants vigilance; hypothesis-generating and should not change practice without controlled data.
BACKGROUND: In driver gene-negative non-small cell lung cancer patients who relapse following radical resection, combination chemotherapy using bevacizumab and platinum-based dual drugs is known to increase both progression-free and overall survival. Treatment initially includes bevacizumab, and if patients are able to tolerate it, bevacizumab can continue to be utilized until disease progression. Bevacizumab is a recombinant humanized monoclonal neutralizing antibody that acts against vascular endothelial growth factor (VEGF). Various anti-VEGF monoclonal antibodies, such as bevacizumab, can increase the risk of arterial thromboembolism. Current data indicate that VEGF-targeted treatment does not significantly increase the risk of venous thromboembolism events, except for bevacizumab. CASE SUMMARY: A 55-year-old man underwent radical resection for cancer of the right lung. Six months following surgery, multiple metastases were observed in his left lung. Subsequently, six cycles of bevacizumab combined with pemetrexed/carboplatin chemotherapy was given. Efficacy evaluation continued to be partial relief according to RECIST 1.1 standards, and no noticeable adverse reactions were noted. After three cycles of maintenance therapy using a combination of bevacizumab and pemetrexed, the patient developed dizziness and dyspnea. The patient was diagnosed with acute cerebral infarction and pulmonary embolism following head magnetic resonance imaging, computed tomography (CT) angiography, and chest enhanced CT. Although the patient received low-molecular-weight heparin anticoagulation and other treatment, the patient eventually died of respiratory failure 1 mo later. This case report may offer some insight into fatal arteriovenous embolism, which has not been previously reported. CONCLUSION: Bevacizumab combined with chemotherapy may also increase the risk of arteriovenous thromboembolism. Accordingly, patients who receive angiogenesis inhibitor therapy should be carefully selected. Furthermore, close monitoring and timely intervention are necessary in order to reduce the risk of such toxicities.
No takes yet. Share an insight, caveat, or question.
Kong et al. (2022) conducted a case report in Advanced non-small cell lung cancer (n=1). Bevacizumab plus chemotherapy was evaluated on Arteriovenous thrombotic events (cerebral infarction and pulmonary embolism). A 55-year-old man with advanced non-small cell lung cancer developed fatal concurrent cerebral infarction and pulmonary embolism six months after initiating treatment with bevacizumab combined with chemotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: